In the absence of reliable OS comparisons, it is unclear whether the optimal strategy for advanced ALK-positive NSCLC is upfront use of a third-generation ALK TKI or a sequential approach with a second-generation inhibitor followed by lorlatinib at progression. Here, ALK is linked to non-small cell lung carcinoma.